The story has been updated to include comments from a conference call.

NEW YORK (GenomeWeb News) – Exact Sciences said today that revenues in the third quarter came in flat year over year as the firm matched consensus Wall Street estimates on the top and bottom line.

For the three months ended Sept. 30, revenues of $1.0 million were even with the year-ago figure and matched the average analyst estimate of $1.0 million. All revenues came from licensing fees both in the most recently concluded quarter and the year-ago period.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.